Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway

Chronic lymphocytic leukemia (CLL) involves a profound humoral immune defect and tumor-specific humoral tolerance that directly contribute to disease morbidity and mortality. CD154 gene therapy can reverse this immune defect, but attempts to do this pharmacologically have been unsuccessful. The immu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lapalombella, Rosa, Andritsos, Leslie, Liu, Qing, May, Sarah E., Browning, Rebekah, Pham, Lan V., Blum, Kristie A., Blum, William, Ramanunni, Asha, Raymond, Chelsey A., Smith, Lisa L., Lehman, Amy, Mo, Xiaokui, Jarjoura, David, Chen, Ching-Shih, Ford, Richard, Rader, Christoph, Muthusamy, Natarajan, Johnson, Amy J., Byrd, John C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2010
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2852364/
https://ncbi.nlm.nih.gov/pubmed/19965642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-09-242438
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars